An open-label, controlled, multi-site, Phase 2 clinical trial to assess the ureagenesis capacity in newborns and infants up to the age of 12 months with neonatal and infantile onset of urea cycle disorders (UCD) using a 15N ammonium chloride tracer compared to newborns and infants without UCD

drug protocol number
HLSC-UCD-01
drug sponsor
Unicyte AG,Aawasserstrasse 2, 6370 Oberdorf NW, Switzerland
drug study
15NH4Cl tracer assay
drug trial site
King Abdulaziz Medical City NG (Riyadh)
drug status
Rejected
drug phase